Ji Hye Lee, Yu Yil Kim, Hyun Joo Heo, Ji Hun Park, Hyung Gu Cho, Geonbo Kim
{"title":"COVID-19疫苗接种后带状疱疹，疼痛药物方面:一项回顾性单中心研究","authors":"Ji Hye Lee, Yu Yil Kim, Hyun Joo Heo, Ji Hun Park, Hyung Gu Cho, Geonbo Kim","doi":"10.17085/apm.22207","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Herpes zoster (HZ) is one of the most common cutaneous adverse reactionsassociated with the coronavirus disease 2019 (COVID-19) vaccine and has been widely reported. This study aimed to evaluate HZ following COVID-19 vaccination from the viewpointof pain management.</p><p><strong>Methods: </strong>A retrospective study was conducted on 42 patients with HZ who visited the painclinic between August 2021 and October 2021. Medical records were reviewed to comparepain severity, treatment methods, treatment duration, and incidence rate of postherpeticneuralgia (PHN) in patients who received COVID-19 vaccination within 6 weeks prior to developing symptoms compared with other patients with HZ.</p><p><strong>Results: </strong>Fourteen patients developed HZ within 6 weeks after vaccination and were significantly younger than the other HZ groups. There were no significant differences in the frequency of prodromal pain, location of pain, pain severity, treatment methods, treatmentduration, or incidence of PHN compared with the other HZ groups.</p><p><strong>Conclusions: </strong>COVID-19 vaccination-related HZ showed clinical features similar to those ofthe other HZ.</p>","PeriodicalId":7801,"journal":{"name":"Anesthesia and pain medicine","volume":"18 1","pages":"57-64"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/1e/apm-22207.PMC9902632.pdf","citationCount":"2","resultStr":"{\"title\":\"Herpes zoster after COVID-19 vaccination, aspect of pain medicine: a retrospective, single-center study.\",\"authors\":\"Ji Hye Lee, Yu Yil Kim, Hyun Joo Heo, Ji Hun Park, Hyung Gu Cho, Geonbo Kim\",\"doi\":\"10.17085/apm.22207\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Herpes zoster (HZ) is one of the most common cutaneous adverse reactionsassociated with the coronavirus disease 2019 (COVID-19) vaccine and has been widely reported. This study aimed to evaluate HZ following COVID-19 vaccination from the viewpointof pain management.</p><p><strong>Methods: </strong>A retrospective study was conducted on 42 patients with HZ who visited the painclinic between August 2021 and October 2021. Medical records were reviewed to comparepain severity, treatment methods, treatment duration, and incidence rate of postherpeticneuralgia (PHN) in patients who received COVID-19 vaccination within 6 weeks prior to developing symptoms compared with other patients with HZ.</p><p><strong>Results: </strong>Fourteen patients developed HZ within 6 weeks after vaccination and were significantly younger than the other HZ groups. There were no significant differences in the frequency of prodromal pain, location of pain, pain severity, treatment methods, treatmentduration, or incidence of PHN compared with the other HZ groups.</p><p><strong>Conclusions: </strong>COVID-19 vaccination-related HZ showed clinical features similar to those ofthe other HZ.</p>\",\"PeriodicalId\":7801,\"journal\":{\"name\":\"Anesthesia and pain medicine\",\"volume\":\"18 1\",\"pages\":\"57-64\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/1e/apm-22207.PMC9902632.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anesthesia and pain medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17085/apm.22207\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anesthesia and pain medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17085/apm.22207","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Herpes zoster after COVID-19 vaccination, aspect of pain medicine: a retrospective, single-center study.
Background: Herpes zoster (HZ) is one of the most common cutaneous adverse reactionsassociated with the coronavirus disease 2019 (COVID-19) vaccine and has been widely reported. This study aimed to evaluate HZ following COVID-19 vaccination from the viewpointof pain management.
Methods: A retrospective study was conducted on 42 patients with HZ who visited the painclinic between August 2021 and October 2021. Medical records were reviewed to comparepain severity, treatment methods, treatment duration, and incidence rate of postherpeticneuralgia (PHN) in patients who received COVID-19 vaccination within 6 weeks prior to developing symptoms compared with other patients with HZ.
Results: Fourteen patients developed HZ within 6 weeks after vaccination and were significantly younger than the other HZ groups. There were no significant differences in the frequency of prodromal pain, location of pain, pain severity, treatment methods, treatmentduration, or incidence of PHN compared with the other HZ groups.
Conclusions: COVID-19 vaccination-related HZ showed clinical features similar to those ofthe other HZ.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
